Heart Transplant http://www.acc.org/Feed?clinicalTopicID=2fbb8575-3ee6-4d6f-8bad-591a0603ecb0 Clinical Topic Feed: Heart Transplant en Extracorporeal Perfusion for Extended Criteria Donor Hearts /Latest-in-Cardiology/Journal-Scans/2024/01/26/15/57/increasing-utilization-of-extended For extended criteria donor (ECD) hearts in donation after brain death (DBD), what is the impact of the use of portable extracorporeal perfusion on donor heart utilization and post-transplant outcomes? 1706289240000 Articles and Stories Outcomes in Women With Cardiogenic Shock /Latest-in-Cardiology/Journal-Scans/2023/11/13/14/49/impact-of-female-sex-aha-2023 What is the survival rate at discharge among women versus men with cardiogenic shock (CS) complicating acute myocardial infarction (AMI-CS) and heart failure (HF-CS)? 1699889100000 Articles and Stories Tacrolimus and Everolimus Against Mycophenolate Mofetil to Prevent Major Adverse Transplant Events in Pediatric Heart Transplant /Latest-in-Cardiology/Clinical-Trials/2023/11/10/05/25/teammate The goal of the TEAMMATE trial was to evaluate everolimus with low-dose tacrolimus compared with tacrolimus with mycophenolate among young patients who were ≥6 months after cardiac transplantation. 1699825320000 Articles and Stories Visual Abstract | Outcomes in Women With Cardiogenic Shock /education-and-meetings/image-and-slide-gallery/media-detail?id=69a701c582854750a0e76b98d2f2175e 1699592400000 Images and Slides What Contributes to Worse Outcomes For Women vs. Men With AMI-CS or HF-CS? /Latest-in-Cardiology/Articles/2023/11/08/15/43/what-contributes-to-worse-outcomes-for-women-vs-men-with-AMI-CS-or-HF-CS-aha-2023 Women with heart failure-related cardiogenic shock (HF-CS) had more vascular complications and worse outcomes than men with HF-CS and more studies are needed to advance therapies, decrease complications and improve outcomes for women with CS, according to a working group report being presented at AHA 2023 and simultaneously published Nov. 6 in JACC: Heart Failure. 1699458360000 Articles and Stories Catheter Ablation in End-Stage Heart Failure With Atrial Fibrillation /Latest-in-Cardiology/Clinical-Trials/2023/08/25/03/45/castle-htx The goal of the CASTLE HTx trial was to determine the potential therapeutic effect of catheter ablation for symptomatic atrial fibrillation (AF) in patients with end-stage heart failure with reduced ejection fraction (HFrEF). 1697486340000 Articles and Stories Outcomes of Heart Transplant Donation After Circulatory Death /Latest-in-Cardiology/Journal-Scans/2023/10/12/17/18/outcomes-of-heart-transplant Do post-transplant outcomes differ between recipients of donation after circulatory death (DCD) heart donors and recipients of donation after brain death (DBD) heart donors? 1697136120000 Articles and Stories Maternal and Pregnancy Outcomes Following Heart Transplant /Latest-in-Cardiology/Journal-Scans/2023/10/10/17/36/maternal-and-pregnancy-outcomes What is the risk of pregnancy and delivery after heart transplantation? 1696962720000 Articles and Stories Hybrid Palliation for Infants With Critical Left Heart Obstruction /Latest-in-Cardiology/Journal-Scans/2023/09/28/17/12/outcomes-after-hybrid What are patient characteristics and factors associated with subsequent outcomes for infants undergoing hybrid palliation for critical left heart obstruction (CLHO)? 1695922920000 Articles and Stories Eagle’s Eye View: Can Apixaban be Used Safely in Patients With AF and End-Stage Kidney Disease? /Latest-in-Cardiology/Articles/2023/09/20/14/13/eagles-eye-view-20sep2023 In this week’s View, Dr. Eagle explores the associations of apixaban dose with safety and effectiveness outcomes in patients with atrial fibrillation and severe chronic kidney disease. 1695225600000 Articles and Stories